Articles

Almost undoubtedly, those with an interest in the patent field will have heard patent attorneys and examiners alike talk about “the skilled person”. This fictitious person represents a standard against which numerous aspects of patentability are assessed. But who is this “skilled person”? What capabilities and expertise do they have,...

On Wednesday 5th June, Gill Jennings & Every hosted an event to investigate how Artificial Intelligence (AI) and Machine Learning (ML) are transforming digital healthcare and pharmaceuticals.  We brought together an expert panel to help us find out more about the different ways AI is being implemented and their advantages...

A further £23 million of funding for UK electric vehicle battery technology has been announced as part of the UK government’s Faraday battery challenge, which aims to boost development of cost-effective, high-performance, durable, safe, low-weight and recyclable batteries. Among the recipients is GJE client Granta Design, who has been awarded...

In Europe, Supplementary Protection Certificates (SPCs) compensate patentees for the inevitable delay in obtaining Marketing Authorisation by extending exclusivity for a marketable pharmaceutical or plant protection product by up to five years (five-and-a-half years for paediatric medicines) following the expiry of the related patent protection. Earlier this year, the EU...

Every so often, the European Patent Office issues a decision on a case which has important consequences for other patent applicants. The recent decision T1085/13 (discussed in greater detail here) has implications for how purity claims are assessed at the EPO and may be seen as patentee-friendly, particularly for the...